Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 10/20 | 0.49 |
| ▸ | CDK9 | P50750 | 10/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067599 | 0.85 | CCNT1 (0.47) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL978744 | 0.82 | CCNT1 (0.63) | CCNT1CDK9LMNATHRB | |
| SCHEMBL979793 | 0.82 | QDPR (0.58) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL979744 | 0.79 | THRB (0.49) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL11956930 | 0.78 | LMNA (0.62) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL14320646 | 0.76 | TDO2 (0.49) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL15615751 | 0.76 | CCNT1 (0.49) | CCNT1CDK9LMNATHRBKDM4E | |
| SCHEMBL24721518 | 0.75 | MMP2 (0.56) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL6437476 | 0.75 | MMP2 (0.49) | CCNT1CDK9MMP2MMP3LMNA | |
| SCHEMBL1103889 | 0.73 | CCNT1 (0.59) | CCNT1CDK9MMP2MMP3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2454251-A1 | GPR119 AGONISTS | Eli Lilly and Company (US) | 2012-05-23 | — | — | EP | disclosed |
| CN-102432598-A | Tricyclic compound, preparation method thereof and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO | 2012-05-02 | — | — | CN | disclosed |
| WO-2011008663-A1 | GPR119 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | CCNT1 4475/4885CDK9 2128/4885MMP2 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.